Amgen’s obesity drug led to high discontinuation rates in mid-stage trial, as company plans to adjust dosing

Amgen's obesity drug candidate, MariTide, demonstrated significant weight loss in its Phase 2 trial, with participants losing up to 16.2% of body weight (up to 19.9% for those completing treatment). However, the study also revealed a high rate of side effects and discontinuations, which validates Amgen's decision to pursue a slower dosing schedule in future testing to improve tolerability. These results, published in the New England Journal of Medicine, highlight MariTide's potent efficacy while underscoring the critical need to address tolerability for its competitive positioning in the evolving obesity drug market.

Analysis

Amgen's Phase 2 trial results for its obesity candidate, MariTide, reveal a potent but problematic profile, highlighting a significant efficacy-versus-tolerability trade-off. The drug demonstrated substantial weight loss, with non-diabetic participants losing up to 16.2% of body weight in an intent-to-treat analysis and up to 19.9% for those who completed the regimen. However, these compelling efficacy figures are counterbalanced by a high rate of side effects, which led to a notable number of discontinuations. This outcome validates Amgen's strategic decision to pivot to a slower dosing schedule for future studies, a necessary step to improve the drug's safety and adherence profile. The divergence between the results for all participants and those who remained on treatment underscores the critical impact of tolerability on the drug's real-world potential and its competitive standing in the burgeoning obesity market.

Key Decisions for Investors

• Investors should view these results as a qualified positive, recognizing MariTide's high efficacy as a key de-risking event but pricing in significant uncertainty until further data on the revised, more tolerable dosing schedule is released.
• Monitor upcoming clinical trial milestones closely, with a specific focus on discontinuation rates and the side-effect profile under the new dosing regimen, as these will be the primary determinants of MariTide's commercial viability.
• Use the reported weight loss figures of 12.3% to 16.2% (intent-to-treat) as a new benchmark for competitive analysis, but weigh this efficacy against the implied tolerability challenges when assessing Amgen's potential market share against incumbent treatments.